v3.26.1
Segment Reporting - Summary of Segment Loss (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Abstract]    
CDMO, CRO and Other Third-party Preclinical Studies, Clinical Trials and Consulting Costs $ 6,213 $ 4,812
Internal research and development personnel costs 1,274 1,069
Other research and development costs 85 149
General and administrative personnel expenses 1,564 677
Other general and administrative expenses 2,697 3,647
Interest expense 0 1,443
Other segment items (977) (1,601)
Net loss $ (10,856) $ (10,196)